Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00177255
Status:
TERMINATED
Last Update Posted:
2016-02-08
First Post:
2005-09-12
Brief Title:
A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers
Sponsor:
University of Pittsburgh
Organization:
University of Pittsburgh
Study Overview
Official Title:
A Phase II Study of Weekly Docetaxel Taxotere in Combination With Capecitabine Xeloda in Advanced Gastric and Gastro-Esophageal Adenocarcinomas
Status:
TERMINATED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Roche has withdrawn support
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase II study that will investigate weekly dosing of docetaxel in combination with capecitabine in advanced gastric and gastro-esophageal adenocarcinomas
Detailed Description:
This is a phase II study that will investigate weekly dosing of docetaxel in combination with capecitabine in advanced gastric and gastro-esophageal adenocarcinomas Docetaxel 30mgm2 will be administered on days 1 and 8 of each cycle and capecitabine 825mgm2 bid total daily dose 1650mgm2 will be administered orally for 14 days days 1-14 of each cycle Each cycle is 21 days Subjects will receive unlimited cycles of docetaxel and capecitabine until there is evidence of disease progression or unacceptable side effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None